SCHEMBL5223022

SCHEMBL5223022

O=C(Nc1ccccc1C(=O)Nc1ccc(Cl)cc1)c1ccncc1

nearest known ligand 0.75

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.75
MAPK1 P28482 1/20 0.73
NPC1 O15118 3/20 0.65
RAB9A P51151 3/20 0.65
LMNA P02545 1/20 0.65
PKM P14618 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
KMT2A Q03164 4/20 0.64
NT5E P21589 1/20 0.64
MEN1 O00255 2/20 0.64
F10 P00742 2/20 0.62
RXFP1 Q9HBX9 2/20 0.60
GAA P10253 1/20 0.59
HTT P42858 1/20 0.59
JAK2 O60674 2/20 0.57
TYK2 P29597 2/20 0.57
KDR P35968 1/20 0.56
NAMPT P43490 1/20 0.56
ALDH1A1 P00352 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12316777 0.89 POLB (0.69) POLBNPC1RAB9AKMT2AMEN1
SCHEMBL11617697 0.85 MAPK1 (1.00) POLBMAPK1NPC1RAB9ALMNA
SCHEMBL10413044 0.85 RAB9A (0.67) POLBMAPK1NPC1RAB9ALMNA
SCHEMBL5226687 0.82 NPC1 (0.74) NPC1RAB9ASMN1; SMN2F10RXFP1
Iodide SCHEMBL5221809 0.81 APOBEC3A (0.64) POLBNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL3005186 0.81 KDR (0.71) KDRNAMPT
SCHEMBL30846489 0.81 KDR (0.71) KDRNAMPT
SCHEMBL1010146 0.80 RXFP1 (0.68) POLBMAPK1LMNARXFP1KDR
SCHEMBL6001715 0.80 POLB (0.68) POLBNPC1RAB9ALMNAPKM
SCHEMBL10179708 0.79 F10 (0.79) F10RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1014962-A4 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2007-06-27 EP disclosed
US-6605626-B2 Benzamide inhibitors of factor Xa ELI LILLY AND COMPANY 2003-08-12 US disclosed
US-20020120007-A1 Benzamide inhibitors of factor Xa BEIGHT DOUGLAS WADE (US) 2002-08-29 US disclosed
US-6313122-B1 AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS ELI LILLY AND COMPANY 2001-11-06 US disclosed
EP-1014962-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-05 EP disclosed
WO-1999000121-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120007-A1 Benzamide inhibitors of factor Xa TFPI, F11, F12 POLB 2711/4885MAPK1 1423/4885NPC1 1618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.